Yuhan Corp stock (KR7000100008): $30M milestone from Lekraza Europe launch

Yuhan Corp announced a $30 million milestone payment following the commercialization start of its lung cancer drug Lekraza in Europe, marking entry into four continents. Cumulative milestones for the FDA-approved drug now total $300 million.

Yuhan Corp will receive $30 million (about 44.8 billion won) in milestone payments after Janssen Biotech began commercializing the combination therapy of Yuhan's Lekraza and Libribant for non-small cell lung cancer in Europe, according to MK as of recent announcement. This is the first new lung cancer drug developed by a Korean firm and approved by the U.S. FDA to reach Asia, Americas, Oceania, and now Europe. The payment brings cumulative Lekraza milestones to $300 million out of a potential $950 million total deal value.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Yuhan Corporation
• Sector/industry: Pharmaceuticals
• Headquarters/country: South Korea
• Core markets: Asia, US, Europe, Japan, China
• Key revenue drivers: Oncology drugs like Lekraza
• Home exchange/listing venue: Korea Exchange (KRX)
• Trading currency: KRW

Yuhan Corp: core business model

Yuhan Corp, a leading South Korean pharmaceutical company, focuses on developing innovative therapeutics, particularly in oncology. The firm has built a portfolio centered on novel drugs like Lekraza (lazertinib), a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC). Yuhan partners with global players such as Janssen Biotech for commercialization, leveraging milestones and royalties for revenue. Last year, the company reported sales of 2.1866 trillion won, marking the second consecutive year exceeding 2 trillion won, according to MK reporting on 2025 full-year figures published recently.

This milestone-driven model reduces development risks while providing upfront and phased payments. Yuhan's strategy emphasizes R&D investment in high-need areas like lung cancer, where Lekraza has gained approvals from the U.S. FDA, Japan, China, and now Europe via partnerships.

Main revenue and product drivers for Yuhan Corp

Lekraza remains the flagship product, with commercialization now spanning multiple continents. The latest $30 million payment follows prior milestones: $50 million upfront, $35 million, $65 million for U.S. launch, $15 million for Japan, and $45 million for China. Cumulative receipts stand at $300 million toward a $950 million total potential. This deal with Janssen underscores Yuhan's growing global footprint in oncology.

Beyond Lekraza, Yuhan generates revenue from established drugs and a pipeline including bioequivalence studies like YHP2508C, as noted on ClinicalTrials.gov. Sales growth reflects strong demand for its NSCLC treatments amid rising global cancer rates.

Industry trends and competitive position

The oncology sector sees robust demand, with NSCLC treatments evolving toward targeted therapies like EGFR inhibitors. Yuhan Corp competes with global leaders but differentiates via Lekraza's profile as a Korean-developed, FDA-approved asset. Its partnerships expand reach into key markets, including the U.S., where FDA approval enhances credibility for American investors tracking Asian biotech growth.

Why Yuhan Corp matters for US investors

Yuhan Corp offers U.S. investors exposure to Asia's burgeoning pharma sector, particularly oncology innovations with FDA validation. Lekraza's U.S. commercialization via Janssen provides direct ties to American healthcare markets, where NSCLC affects over 200,000 patients annually. Traded on KRX with ISIN KR7000100008, the stock appeals to those seeking diversified international pharma plays amid U.S. market volatility.

Conclusion

Yuhan Corp's $30 million milestone from Lekraza's European launch highlights its progress in global oncology markets. With sales surpassing 2 trillion won for the second year and a robust milestone pipeline, the company demonstrates sustained growth. U.S. investors may note its FDA-approved asset and partnerships as key factors in its international expansion, though market dynamics remain fluid.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.